


TRUPCR® HPV HR with 16 & 18 Differentiation Kit (Single tube)

NEED

Human Papillomaviruses (HPV) infections are among the most common sexually transmitted infections. Persistent infection with human papillomavirus (HPV) is the principal cause of cervical cancer. The presence of HPV has been implicated in more than 99% of cervical cancers worldwide, including both cervical squamous cell carcinoma and cervical adenocarcinoma. In 2018, an estimated 570,000 women were diagnosed with cervical cancer worldwide and about 311,000 deaths were reported due to this disease. HPV High Risk testing in cervical cancer screening offers a high degree of certainty.



SOLUTION BY TRUPCR®

TRUPCR® HPV HR with 16 & 18 Differentiation Kit (Single tube) is an in-vitro nucleic acid amplification assay for the detection of 14 high risk HPV along with the differentiation of HPV 16 & 18 DNA in a single tube from clinical samples using Real time PCR system.

An Endogenous Internal Control is incorporated into the kit to verify the quality of samples, quality of extracted DNA, amplification procedure and possible presence of inhibitors, which may cause false negative results and this design, makes this kit highly reliable.


TARGET GENOTYPES

Primer Probe Mix


FAM	Tex Red	HEX	Cy5
HPV HR	HPV 16	HPV 18	Endogenous IC




KEY FEATURES



Endogenous Internal Control incorporated within the kit to ensure reliable results



Complete workflow solution available from Extraction of sample to Post-PCR analysis



Platform agnostic as compatible with various platforms



Rapid and reliable results within 90-100 minutes after PCR Start

TECHNICAL SPECIFICATIONS

- Sample Type – Cervical Swab Specimen, Urine Specimen, FFPE Sample
- Clinical Validation – Validated on more than 1000 clinical samples
- Target Regions – E6/E7 region by primer and probes specific for HPV 14 Genotypes (16/18/31/33/35/39/45/51/52/56/58/59/66 and 68)
- Reaction Volume – 30 µl in each tube
- LOD Data: 100 IU/ml
- Compatible Instruments – Applied Biosystems™ 7500 series, Applied Biosystems™ QuantStudio® 5, Rotor-Gene Q, Bio-Rad CFX96

CLINICAL DATA

		Reference Method		
		Positive	Negative	Total
TRUPCR Method	Positive	132	1	133
	Negative	1	126	127
Total		133	127	260

Parameters	Estimate
Sensitivity	99.25%
Specificity	99.21%
Positive Predictive Value	99.25%
Negative Predictive Value	99.21%



ORDERING INFORMATION

Cat. No.	Description	Size
3B1439	TRUPCR® HPV HR with 16 &18 Differentiation Kit (Single tube)	48 Reactions
3B1440	TRUPCR® HPV HR with 16 &18 Differentiation Kit (Single tube)	96 Reactions

PUBLICATIONS

1. Comparison of treatment response in cervical carcinoma patients infected with human papillomavirus 16 and human papillomavirus 18 who are treated with chemoradiation (<https://www.cancerjournal.net/preprintarticle.asp?id=286538>)
2. Role of HPV DNA Testing and its influence on clinical outcomes in Cervical Cancer. (https://www.posteressiononline.eu/173580348_eu/congresos/ESTRO38/aula/-EP_1486_ESTRO38.pdf)